FIELD: medicine, pharmaceutics.
SUBSTANCE: there are described new triazolium salts of general formula (I) 
stereo- and tautomer forms and physiologically acceptable salts thereof, wherein X- C-R1 or N, R1-hydrogen, C1-6alkyl or halogen; A- is an anion of a pharmacologically acceptable organic or inorganic acid; Q1 is hydrogn, -C1-6alkyl optionally substituted, -C3-6cycloalkyl, -C(O)-O-R11 or - C(O)-R11; R11 -C1-6alkyl; Q2 and Q3 are hydrogen; R2- R9 independently mean hydrogen, -C1-6alkyl optionally substituted, -O-(C1-8)alkyl optionally substituted, etc., and using the above compounds as a drug preparation.
EFFECT: compounds possess antithrombotic activity, particularly, they inhibit the protease-activated receptor 1 (PAR1), and may be used in treating the diseases such as myocardial infarction, angina, stroke, and others.
4 cl, 2 tbl, 86 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION AND USE THEREOF AS MEDICINAL AGENTS | 2009 |
|
RU2499797C2 |
| TRICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USING THEM FOR TREATING IMMUNOLOGICAL AND ONCOLOGICAL COMPOUNDS | 2009 |
|
RU2545023C9 |
| AMINOQUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | 2020 |
|
RU2821714C2 |
| TARTRATE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446160C2 |
| ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446157C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
| PYRIMIDINE DERIVATIVES AND USE THEREOF IN TREATING RESPIRATORY DISEASES, SUCH AS COPD | 2011 |
|
RU2604719C2 |
| CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
| PYRIMIDINE DERIVATIVES AND USING THEM IN TREATING RESPIRATORY DISEASES, SUCH AS COPD | 2011 |
|
RU2581839C2 |
